Intermittent claudication (cladicatio intermittens) is a symptom of atherosclerosis. The disorder causes pain in the muscles of the legs while walking, and pain subsides after a few moments of rest.

Conclusions

• In patients with intermittent claudication, cilostazol enables some extension in the maximum walking distance (when pain prevents further walking) compared to placebo. No studies have reported follow up beyond 6 months.
• The effects of cilostazol in relation to smoking cessation and supervised walking exercise have not been studied. Studies have not reported whether the control groups have been helped by smoking cessation and supervised walking exercise. No studies have investigated whether cilostazol can improve the results in patients that have received such help.
• Side effects such as headache and gastrointestinal symptoms are more common with cilostazol treatment than with placebo. The studies are not designed to be large enough to enable an assessment of risk for serious and uncommon side effects.
• The scientific evidence is insufficient to determine whether cilostazol treatment for intermittent claudication is cost­effective.